Testing effectiveness (Phase 2)Study completedNCT03839446
What this trial is testing
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
Who this might be right for
Acute Myeloid Leukemia
Robert Redner, MD 16